Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.31 -2.32 (-2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
News headline image
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss ↗
 
Via Benzinga
News headline image
Stock Market Rally Under Pressure As Walmart, Target Crash On Inflation Woes: Weekly Review ↗
A confirmed market uptrend is reeling as inflation's pain bites. 
Via Investor's Business Daily
News headline image
4 Analysts Have This to Say About Incyte ↗
Analysts have provided the following ratings for Incyte (NASDAQ:INCY) within the last quarter: 
Via Benzinga
News headline image
Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance ↗
 
Via Benzinga
News headline image
Incyte: Q1 Earnings Insights ↗
Incyte (NASDAQ:INCY) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted ↗
 
Via Benzinga
News headline image
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas ↗
Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The... 
Via Benzinga
News headline image
Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now ↗
The race is on in eczema treatment as the biggest name faces new rivals. 
Via Investor's Business Daily
News headline image
FDA Approves Lilly and Incyte's OLUMIANT (baricitinib) for Hospitalized Patients with COVID-19 ↗
The U.S. Food and Drug Administration (FDA) has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized patients. 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
News headline image
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
News headline image
Global Cord Blood Enters Therapy Market Via Cellenkos Acquisition For Over $600M ↗
Global Cord Blood Corporation (NYSE: CO) will acquire Cellenkos Inc and the rights to develop and commercialize all of its existing and future products worldwide. 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
3 Nasdaq Stocks to Buy Now for Growth ↗
These are the best Nasdaq stocks to invest in now. INCY, ROKU and FTXL can make great investments in the rest of the year. 
Via InvestorPlace
News headline image
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
From Incyte
Via Business Wire
News headline image
EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting ↗
 
Via Benzinga
News headline image
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
From Incyte
Via Business Wire
News headline image
How To Attend Incyte Q1 2022 Earnings Conference Call ↗
Incyte (NASDAQ:INCY) will host a conference call at 08:00 AM ET on May 3, 2022, to discuss Q1 2022 earnings results. How to Attend Incyte (INCY) Conference Call Follow this link to access the live... 
Via Benzinga
News headline image
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
News headline image
The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
This Favorable Sign Appears On Incyte's Chart ↗
If history is any guide, there may be good fortune ahead for shares of Incyte (NASDAQ:INCY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
News headline image
Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder ↗
Incyte Corporation (NASDAQ: INCY)  
Via Benzinga
News headline image
Incyte-Lilly's Olumiant Continue To Show Improved Scalp, Eyebrows, Eyelash Hair Regrowth At 52 Weeks ↗
At the American Academy of Dermatology Annual Meeting, Eli Lilly And Co (NYSE: LLY) and Incyte Corp (NASDAQ: INCY)  
Via Benzinga
News headline image
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
From Incyte
Via Business Wire
News headline image
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
From Incyte
Via Business Wire
< Previous 1 2
...
21 22 23 24 25 26 27 28 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.